{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260817534800/en/TAGRISSO%C2%AE-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-MET-driven-EGFR-mutated-lung-cancer-after-progression-on-TAGRISSO", "message": "News view counter 886435 successfully enlarged"}